Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on August 9, 2021. The report addresses a specific corporate governance event regarding the company's listing status on the Nasdaq Capital Market. Note: The request metadata references "Envue Medical, Inc.," but the filing text explicitly identifies the registrant as NanoVibronix, Inc.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on stock price compliance metrics.
- Stock Price Compliance: The company's common stock closing bid price was at least $1.00 per share for 10 consecutive business days (July 26, 2021, to August 6, 2021).
Material Changes
The primary material change reported is the resolution of a listing deficiency. On June 17, 2021, the company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a closing bid price below $1.00 for 30 consecutive business days. As of August 9, 2021, the company has regained compliance, and the matter is closed.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or management commentary regarding operations. The primary risk addressed was the potential delisting from the Nasdaq Capital Market, which has been mitigated by the restoration of the minimum bid price requirement.
Investor Verification Checklist
- Verify the current trading status of NanoVibronix, Inc. (NAOV) on the Nasdaq Capital Market.
- Confirm the company's continued compliance with the $1.00 minimum bid price requirement in subsequent reporting periods.
- Review the company's most recent 10-Q or 10-K for actual financial performance data, as this 8-K contains no financial statements.